Today, we launched our FY26 full-year results. FY26 was a year of transition and setting a path to return to sustainable growth. To learn more about our results and how we’ve simplified the business and invested in our commercial capabilities, visit our Investor Centre: investors.csl.com #CSL

Today, we broke ground on a $1.5 billion investment to expand our plasma manufacturing capacity in Kankakee, Illinois.

Read how this will support the production of plasma-derived therapies and create new jobs in the US: newsroom.csl.com/2026-03-09-CSL…

#CSL #PlasmaDerivedTherapies #RareDisease

Today we announced our half‑year results. Read the full ASX announcement for details: bit.ly/4tzf89M #CSL

Today we’ve announced that Gordon Naylor has been appointed interim Chief Executive Officer and Managing Director, following Dr Paul McKenzie’s decision to retire. Read more: bit.ly/46DKj9K

Today, we announced an upcoming $1.5b in future U.S. capital investments, further strengthening our contribution to the U.S. healthcare ecosystem. This expansion builds on our significant U.S. presence and over $3b invested since 2018. This investment will generate hundreds of obs and substantially bolster U.S. manufacturing for critical plasma-derived therapies.

Our goal is to meet the growing clinical need for these life-saving medicines, which are often the sole effective treatments for many rare and serious diseases. We are proud to continue investing in American innovation and talent. newsroom.csl.com/2025-11-18-CSL…

#CSL #USManufacturing #PlasmaDerivedTherapies #HealthcareInnovation #AmericanJobs

October is #PlasmaAwarenessMonth, an opportunity to thank our plasma donors for their generosity and to bring awareness of the important role that plasma plays in helping patients.

Our plasma-derived therapies are made possible by the donation of plasma, and these therapies certain serious and rare conditions, including immune deficiencies and bleeding disorders. In certain medical situations, plasma-derived products may also be used in trauma care and maternal health.

We encourage everyone to learn more about the #PowerofPlasma, to share the message, and consider becoming a donor themselves. Learn more here: csl.com/we-are-csl/our… #CSLPlasma #PlasmaAwarenessMonth #DonatePlasma

Today we shared our full-year results for FY25. Take a look at some of the key financial and operational highlights. For more details visit our Investor Centre: investors.csl.com #CSL #FullYearResults

The first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of #HAE has been authorized by Health Canada, offering those living with HAE a convenient administration approach. Read more: bit.ly/46MYCtN

Applications for the 2026 CSL Centenary Fellowships will close on 30 June. We are inviting Australia’s top early-mid career scientists to apply for next year’s fellowships now. bit.ly/466kBez

Innovation meets convenience with our first homegrown mAb to gain approval, offering a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community. bit.ly/4jZZuOH

@CSL Behring exemplifies the enduring #partnership between Australia and Switzerland, merging Australian #innovation with Swiss precision.

It was a pleasure to attend the 25th Anniversary of CSL Behring celebrations in Bern yesterday.

@CSLVifor

The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa to prevent attacks of HAE. This reflects our commitment to HAE patients around the world, a community we have proudly supported for over four decades. Read more: bit.ly/3FFkoEI.

Dr @QiZhang85 from @SAiGENCI, @UniofAdelaide is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3FxGI2Z

.@DrClareWeeden from @WEHI_research is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3SmhVS7 #CSL

Applications are open for the 2026 CSL Centenary Fellowships. Australian early-mid career biomedical #researchers are invited to apply for 1 of 2 A$1.25m #grants over 5 years. bit.ly/4mcIkzk

Congratulations to the eight medical researchers who have been awarded a CSL Research Acceleration Initiative (RAI) partnership to fast-track the discovery of innovative biotherapies to address unmet medical needs. bit.ly/4cLXPKw

CSL is proud to sponsor the symposium "WHO guidance on PBM implementation: Strategies for effective dissemination and communication" at @NATAforum. We look forward to welcoming you on Thursday 24 April at 12:15 CET!

Japan’s MHLW approved our first-in-class monoclonal antibody for HAE, reinforcing our commitment to a community we have supported for more than 40 years. Japan joins Australia, the UK, and the EU in offering an innovative treatment to patients. Learn more: bit.ly/4bqvtVD

The European Commission’s approval of our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE reflects our ongoing commitment to improving the lives of people living with this condition.

Along with our partner @ArcturusRx, we are proud to announce that the EC has approved the first self-amplifying mRNA COVID-19 vaccine in the European Union. Read more: bit.ly/47HgF1z.